



# 2025 SUSTAINABILITY REPORT

---

Eyebright Medical Technology (Beijing) Co., Ltd.



# CONTENTS

About the Report	01
Statement of the Board of Directors	03
Message from the Chairman	04
Performance Highlight in 2025	05
About Eyebright Medical	07
Sustainability Management	15

## 01 Environmental

### Environmental Management

Environmental Management System	20
Environmental Risk Management	22

### Pollution Prevention

Wastewater Management	24
Waste Gas Management	25
Waste Management	26
Noise Management	27

### Resource Management

Water Resource Management	28
Energy Management	28
Green Production	30
Green Office Practices	31

### Climate Action

Climate-Related Risks	31
Climate Resilience and Adaptation	33
Greenhouse Gas Emissions	35
Ecosystem and Biodiversity Protection	35

## 02 Social

### Innovation Empowerment

Scientific Research Framework	37
R&D Investment	38
Recently Introduced Products	38
Intellectual Property Protection	39
Experimental Ethics	40

### Collaborative Industry Advancement

Academic Exchange	41
Standard Establishment	43
School-Enterprise Cooperation	44
Training & Empowerment	45
Accessibility of Medical Services	47

### Product Responsibility

Quality Management	48
Customer Service	49
Sustainable Supply Chain	50

### Employee Development

Employee Rights Protection	51
Cultivation and Development	52
Welfare and Care	55
Occupational Health and Safety	59

### Serve the Society

Rural Revitalization	60
International Aid Initiatives	61
Medical Donations	62
Charity Activities	63
Science Popularization	65

## 03 Governance

### Corporate Governance

Governance Structure	68
Board and Management Operations	69
Information Disclosure	70
Investor Relations Management	71
Investor Returns	72
Market Capitalization Management	72

### Risk Management and Control

Compliance and Internal Control Management	73
Related Party Transactions and Control	73
Management of Public Opinion	74
Anti-Fraud and Anti-Corruption Measures	74
Anti-Unfair Competition Practices	75
Reporting Mechanism	75
Information Security & Data Privacy	76

### Appendix

78



# About the Report

## Report Overview

Eyebright Medical Technology (Beijing) Co., Ltd. (hereinafter referred to as "Eyebright Medical," "the Company," or "we") has systematically established an ESG management framework to achieve an in-depth integration of shareholder rights protection and sustainable corporate development.

### Report Scope

The scope of this report encompasses Eyebright Medical and its affiliated subsidiaries.

### Reporting Period

This report covers the period from January 1st, 2025, to December 31st, 2025.

### Information Sources

The data used in this report is sourced from public data released. Unless otherwise noted, all non-financial data for 2025 is drawn from the Company's headquarter. The Company assures that the content of this report does not contain any false records, misleading statements, or material omissions.

### Important Notice

This report has been reviewed and approved by the Company's board of directors for public disclosure. The Company and the board assure that the content of this report does not contain any false records, misleading statements, or material omissions.

## Basis for Compilation

- Global Reporting Initiative The GRI Standards
- Guidelines No. 14 of Shanghai Stock Exchange for Self-Regulation of Listed Companies--Sustainability Report (Trial)
- Guide No.13 for Self-Regulatory Supervision on Listed Companies of the SSE STAR Market-Compilation of Sustainable Development Reports
- United Nations "Guidelines for Corporate Action on the Sustainable Development Goals (UNSDGs)"

## Access Information

The bilingual electronic version of the Report is available for downloading from the Eyebright Medical official website ([www.ebmedical.com/en](http://www.ebmedical.com/en)) and the Shanghai Stock Exchange website ([www.sse.com.cn](http://www.sse.com.cn)).

For any enquiry or suggestions regarding the Report, please contact us via: [investors@ebmedical.com](mailto:investors@ebmedical.com) or (86)10-89748322. In case of any discrepancy or inconsistency in the versions, the Chinese version shall prevail.

## Statement of the Board of Directors

The board of directors of Eyebright Medical assume overall responsibility for the accuracy, completeness, and timeliness of the content and information disclosed in this report. As the core decision-making body of corporate governance, the Board is fully and deeply responsible for matters related to Environmental (E), Social (S), and Governance (G).

In the formulation of the ESG governance strategy, the Board has opportunities, the Board employs a rigorous and professional approach, helping identify risks early and seize opportunities, ensuring a solid foundation for the Company's stable development.

The board has established a comprehensive oversight mechanism, closely monitoring the progress of various ESG initiatives to ensure that strategic decisions can be effectively implemented. At the same time, the board continuously tracks the progress of ESG-related goals and adjusts strategies and action plans in a timely manner based on actual conditions, ensuring that the Company continues to make positive progress in the ESG field.

The board places great importance on information disclosure. Each year, the board conducts a rigorous review of the Company's ESG report to ensure that the report accurately and truthfully reflects the effectiveness and reliability of the Company's ESG efforts.

This Report provides a detailed disclosure of Eyebright Medical's progress and achievements in ESG work in 2025, having been reviewed and approved at the meeting of the board of directors.





## With Light in the Heart, Progress Moves Steadily Forward

— Message from the Chairman

Dear Shareholders, Partners, and Friends from all walks of life,

In 2025, policy shifts and market headwinds led to the Company's first net profit decline. Guided by the Board, we maintained strategic focus by prioritizing innovation, efficiency, and product optimization to navigate these cycles. We remain confident that long-term value is grounded in technological barriers, continuous iteration, and sustained responsibility.

Over the past year, we advanced our three core segments. Surgical treatment scaled core products such as Prosert Intraocular Lens<sup>®</sup> and The Loong Crystal<sup>™</sup> PR Phakic Intraocular Lens, achieving steady market expansion. Myopia management had a steady growth. The AI smart fitting platform improved clinical efficiency, while R&D for new products maintained our leading edge. In myopia control, the “Healthcare + Consumer” strategy drove expansion and improvements via the launch of silicone hydrogel lenses, functional lenses, and care solutions.

The Company pursued synergistic growth through the acquisition of Delta Medical, entering the sports medicine sector, and strategic overseas M&A via our Hong Kong subsidiary to establish a European foothold. As an ophthalmic tech leader, we fulfill our social responsibilities through our core business, while deeply integrating ESG principles—including compliance, talent empowerment, and green practices—into our core operations.

Looking ahead to 2026, the Company will focus on high-end innovation, deepen M&A integration, and advance global deployment, steadfastly protecting nationwide eye health with greater resolve and concrete action.

With light in the heart, there is no fear of darkness. With steady progress and long-term vision, we will ultimately reach faraway goals.

Eyebright Medical Technology (Beijing) Co., Ltd.

April 2026

Xie Jiangbing

# Performance Highlight in 2025

## Business Highlight

Operating Revenue RMB **1,482.70** Million

Y-O-Y Growth **5.15%**

Net Income Attributable to Shareholders RMB **268.17**

Million | Y-O-Y Growth **-30.96%**

Total Assets RMB **3,887.87** Million

Equity Attributable to Shareholders RMB **2,788.73**

Million

Basic Earnings per Share RMB **1.40**

Weighted Average Return on Equity **10.15%**

## Innovation Empowerment

Research and Development Personnel **289**

R&D Investment RMB **156** Million

Patents Applied **61**

Patents Granted **41**

Total Patents Applied **480**

Total Authorized and Valid Patents **291**

Participation in Standard Formulation and Industry

Report Compilation **9**

## Environmental Highlight

**ISO 14001** EMS Certification

**ISO 50001** EnMS Certification

The Headquarter recognized as a "**Beijing Green Factory**"

Conducted inaugural **GHG inventory**

## Product Quality

External Audits Conducted **19** times

National Supervision Pass Rate **100%**

## Employee Development

Total Employees **2,331**  
Percentage of Female Employees **61%**  
Percentage of Female Executives **50%**  
Cash Paid to Employees RMB **383** Million  
Y-O-Y Growth **13.21%**  
Training Sessions Conducted **224**  
Total Training Duration **17,536** Hours  
Total Number of Participants in Training **5,269**  
Employees with Equity Incentives **77**  
Total Incentivized Shares **265,032** Shares

## Governance Performance

Total Board and Committee Meetings Held **16**  
Disclosed Regular Reports **4**  
Interim Announcements **52**  
Three Consecutive Years of Information Disclosure  
Rating Grade **A**  
Earning Calls Briefings Held **6**  
**No** Insider Trading  
**No** Correction Announcements

## Community contribution and Social Recognition

Domestic Tax Paid RMB **159.20** Million  
Hosted or Participated in Science Popularization and Charity Activities **17**  
Total Honors Received Throughout the Year **40+** Honors

# About Eyebright Medical

Eyebright Medical Technology (Beijing) Co., Ltd. is a national high-tech enterprise and a national-level specialized and innovative "little giant" enterprise founded by Dr. Xie Jiangbing. The Group's headquarter is in the Zhongguancun Science Park in Beijing, with subsidiaries established in Shanghai, Suzhou, Lianyungang, Yantai, Hong Kong and Switzerland. After ten years of high-quality innovative development, the Company was listed on the STAR Market of the Shanghai Stock Exchange in 2020, with the stock name "Eyebright Medical" and stock code: 688050.


The Company's balanced product portfolio spans three major areas of the ophthalmic field: cataract surgery, myopia management, as well as consumer vision care. Adhering to its five proprietary technology platforms, balanced product portfolio, the Company has established a competitive advantage and entry barriers in China, striding into a world-leading medical enterprise on behalf of China's "intelligent manufacturing" power.

## Business Layout

### Surgical Treatment



The Company has developed and produced several domestic pioneering and market-leading intraocular lenses, including over 20 models such as aspheric, multifocal, extended depth of focus (EDF). In 2025, The Company has launched China's first aspheric phakic intraocular lens products, the Loong Crystal™ PR.






## Myopia Management

As a technological pioneer in myopia management, the Company launched the world's first full-arc aspheric orthokeratology lenses. Other myopia management products include defocus glasses, daily wear rigid contact lenses, defocus soft lenses, and related care products.



## Consumer Vision Care

As a core player in consumer vision care, the Company possesses proprietary technologies for contact lenses and has established an integrated industrial layout spanning R&D, manufacturing, and sales. Leveraging strengths, We are developing premium lenses with enhanced comfort, safety, and functionality.



## Company Culture

Vision

Illuminate Your World

Mission


Provide world-class ophthalmic technologies, products and services

Core Values

Innovative and Enterprising  
Openness and harmony  
Honesty  
Sharing Success

## Development Strategy

Eyebright Medical is dedicated to providing cutting-edge ophthalmic technologies, products, and services to ophthalmic patients and vision care consumers worldwide. The Company will continue to implement a dual-driven strategy of "Healthcare+ Consumer" alongside international development, continually extending its product portfolio to provide comprehensive ophthalmic care solutions worldwide.



**Case**

In 2025, China's first aspherical phakic intraocular lens and Proming® Extended Depth of Focus Intraocular Lens were approved for market launch via the NMPA. Additionally, the Company's self-developed high-Dk silicone hydrogel contact lens received regulatory registration.

**Case**

Driven by the growth strategy, the Company acquire a controlling stake in Delta Medical, an international sports medicine company covering the full care cycle from prevention to rehabilitation. This move leverages Delta's integrated capabilities in implants, instruments, and equipment to extend the Company's R&D and management strengths into the high-potential medicine sector, creating new profit drivers and securing long-term growth.

**Case**

The Company's 24-hour smart contact lens stores are included into the "2025 Key Application Scenario Support Project List" list and the commercial deployments of embodied AI are being recognized. Powered by Galaxy's humanoid robots, stores are now open in major cities across China, offering a testbed for embodied AI and ready to expand nationwide.

**Case**

In 2025, the Company boosted its global presence by showcasing ophthalmic products across three key sectors at major international forums and industry exhibitions. Through in-depth exchanges on cutting-edge technologies and trends with global stakeholders, the Company significantly enhanced its international influence.

## Development History

**2010-2014**

### Early Technology Accumulation

**2010** Company Founded

**2014** Launch our first Aspheric IOL, Proming® A1-UV, the First Domestically-Manufactured IOL with Independent Intellectual Property Rights

**2015-2019**

### Expanding Product Portfolio and Rapid Commercialization

**2016** NMPA Approval Granted for our Toric IOL

**2019** iBright® RGP Contact Lens has received NMPA approval

Domestic Users are Covered by Over 2,000 Ophthalmology Hospitals





## 2020-2025

### 2020-2025 Initiation of Public Market Listing and Expansion of Operations

- 2020** Listed on the Shanghai Stock Exchange's STAR Market
- 2021** Completing the acquisition of Tianyan Medicine, the Company enter into the Soft Contact Lens Market
- 2022** Yantai Production facilities has operated  
Proming Continuous Vision Received NMPA Approval
- 2023** Controlling interest in Fujian Unicon Optical Co., Ltd.  
Established Eyebright Hong Kong advance Internationalization Strategy
- 2024** Beijing Medical Device R&D Center and Production Base Inaugurated  
Beijing Future Science City Marketing Center in Operation  
Strategic Cooperation with Meituan Medicine to Launch 24-hour Smart Stores for Contact Lens
- 2025** China's first aspheric phakic intraocular lens product, the Loong Crystal™ Phakic Intraocular Lens has received NMPA Approval  
Proming® Extended Depth of Focus intraocular lens Received NMPA Approval  
Self-developed High-Dk Silicone Hydrogel Contact Lens Received NMPA Approval  
Established Eyebright Switzerland  
Acquired OphthalmoPro GmbH



## Awards and Recognitions

### Beijing Headquarter

Beijing Top 100 Private Enterprises

2025 Beijing Top 100 SRDI Enterprises

2025 Beijing Top 100 High-precision, Advanced and Cutting-edge Enterprises

2025 Beijing Top 100 Manufacturing Enterprises

Excellent Private Science and Technology Enterprise

Beijing Intellectual Property Advantageous Unit

Top 500 New Economy Enterprises

Top 30 STAR Market Listed Companies

SSE Eagle · Golden Quality Award – Sustainable Growth

Securities Daily · Golden Steed Award- Most Valuable Investment Listed Company

Securities Daily · Golden Junma Award - Listed Companies with the Most Investment Value

China Listed Company Tianma Award - Investor Relations Management Innovation Practice Award

Global Ophthalmic International Cooperation Award

The 16th China Listed Company Investor Relations Pegasus Award

2025 China Listed Company Yinghua Award-A-Share Value Demonstration Case

2025 Listed Company Internal Control Best Practice Case

2025 Listed Company Board Office Best Practice Case

Listed Company 2024 Annual Report Performance Briefing Best Practice Case

2025 Listed Company Board Typical Practice Case

Beijing Changping District 2024 Excellent Science Popularization Base

Beijing Changping District "Rule of Law Assisting Enterprises · Dual Exemption Whitelist" Category I Enterprise



## Holding Subsidiaries

2025 Jiangsu Gazelle Enterprise, Jiangsu SRDI Enterprise, Jiangsu Enterprise Technology Center  
 Fujian "Gazelle" Innovative Enterprise in the Core Industry of Digital Economy  
 Jiangsu Gazelle Enterprise  
 Taobao Flash Buy Medicine Annual Growth Brand, New Retail Pioneer Award  
 Advanced Unit in Optometry and Ophthalmology

## Products Awards

Beijing 2025 First Batch Catalog of Major Technical Equipment  
 The 19th Beijing Invention and Innovation Competition Gold Award  
 Certificate of Scientific and Technological Achievement  
 Beijing New Technology and New Product



## Sustainability Awards

2025 Listed Company Sustainability Best Practice Case  
 Gold Seal of the Pilot Program for Climate-related Financial Disclosures  
 Wind ESG Rating Level A



# Sustainability Management

Eyebright Medical has continued to advance human vision health with a commitment to aligning social responsibility with sustainable corporate development. As a responsible corporate citizen, the Company works steadily to fulfill its mission. Based on our actual capabilities and seize opportunities arising from the changing environment in the new era. The Company further strengthen our initiatives in Environmental, Social and Governance (ESG) and proactively respond to the concerns and expectations of both internal and external stakeholders.

## United Nations Sustainable Development Goals



## ESG Strategic Planning



The Company continuously optimize the governance framework, identify and assess key risks, and develop measures to establish a standardized, transparent, and fair governance mechanism that ensures sustainable development.



R&D innovation drives our sustainable growth. The Company will increase investment to develop cutting-edge ophthalmic technologies and products.



The Company prioritize employee rights by fostering a diverse, inclusive, and equitable work environment. The Company will remain actively involved in social welfare activities, leveraging our expertise to contribute greater value to society.



## ESG Management System

To enhance ESG management practices, Eyebright Medical has established a multi-tiered management system. The board, as the supreme decision-making body, oversees ESG strategy and disclosure annually. Senior Management integrates ESG principles into all business processes, while a dedicated ESG Task Force spearheads action plans for key initiatives. Meanwhile, designated liaisons across functions and subsidiaries ensure efficient data collection and report compilation. This systematic mechanism aligns ESG goals with business growth, ensuring effective implementation organization-wide.





## Stakeholder Communication

Stakeholders	Expectations and Demands	Response Methods/Communication Channels
Shareholders	<ul style="list-style-type: none"> <li>•Regulated Corporate Governance</li> <li>•Sustained Value Creation</li> <li>•Information Disclosure</li> </ul>	Enhance corporate governance and investor relations involves, and use online platforms to promptly address investor inquiries. Deliver consistent profitability and timely financial disclosures
Customers	<ul style="list-style-type: none"> <li>•Product Safety and Quality</li> <li>•Diverse Offerings</li> <li>•Privacy and Information Security</li> <li>•Responsible Marketing</li> </ul>	Provide high-quality products and services, implement robust information security measures to ensure the protection of customer privacy
Employees	<ul style="list-style-type: none"> <li>•Basic Rights Protection</li> <li>•Training and Promotion</li> <li>•Compensation and Benefits</li> <li>•Health and Safety</li> <li>•Work-Life Balance</li> </ul>	Sign labor contracts and remits social insurance in compliance with local law. Maintain competitive salary levels, provide multidimensional trainings for employees. Maintain rigorous occupational health and safety standard
Environmental Groups	<ul style="list-style-type: none"> <li>•Environmental Protection</li> <li>•Reduce Pollution Emissions</li> <li>•Enhance Energy Efficiency</li> </ul>	Establish mid-to long-term environmental management goals, implement energy-saving and emission-reduction initiatives, and promotes green office practices
Partners	<ul style="list-style-type: none"> <li>•Win-Win Cooperation</li> <li>•Sustainable Supply Chain</li> <li>•Contribute to Industry Development</li> </ul>	Establish standardized procurement systems and enhances supply chain management, maintain a fair and orderly competitive environment. Build academic exchange platforms and conducts industry training, initiates industry-university-research cooperation projects
Government and Regulatory Authorities	<ul style="list-style-type: none"> <li>•Operate in accordance with the law</li> <li>•Comply with business ethics</li> </ul>	Fulfills tax obligations, enhance anti-bribery and anti-corruption measures

## Materiality Assessment

Conducting a materiality assessment is fundamental to the Company. During the Reporting Period, the Company employed surveys and internal workshops to evaluate issues based on two dimensions: financial materiality (impact on the Company) and impact materiality (effect on the economy, environment, and society). The assessment results have been systematically integrated into our enterprise risk management framework, with key stakeholder priorities disclosed in this Sustainability Report. The specific methodology is as follows:



# Environmental

Eyebright Medical incorporates green development into its business strategy and operations. By enhancing environmental awareness, optimizing resource use, minimizing waste, and adopting sustainable practices, the Company proactively assumes environmental responsibilities, fostering harmonious coexistence between humans and nature.



# Environmental Management

Eyebright Medical diligently fulfills its environmental responsibilities, enhances its management systems, and implements eco-friendly practices. The Company promotes renewable energy and sustainable development, striving for a mutually beneficial relationship between economic performance and environmental protection.

## Environmental Management System

The Company strictly complies with the Environmental Protection Law of PRC and integrates environmental management throughout its operations. In 2025, it enhanced its environmental management system by optimizing processes and upgrading facilities, significantly improving governance effectiveness. In March 2025, the Company obtained ISO 14001 certification, signifying a new level of standardization in its environmental management practices.



### Compliance Management and Audit Oversight

The Company implements the environmental impact assessment system to ensure approvals and completion of EIA and environmental acceptance inspections. It conducts regular self-inspections and audits to guarantee environmental compliance.

### Organizational Structure and Goal Management

The Company has established a robust environmental management framework with designated focal points. Detailed EHS goals are decomposed to specific roles, linked to performance appraisals, and managed through a closed-loop system.

### System Development and Certification

The Company optimizes its environmental management processes and has achieved ISO 14001 and ISO 50001 certifications, aligning its practices with international standards.

### Key Initiatives for Green Transition

During the Reporting Period, the Company's headquarter was recognized as a "Beijing Green Factory" by the Government.



Multiple clean production improvement plans were systematically implemented, enhancing resource utilization efficiency.

### Environmental Investments

During the Reporting Period

dedicated environmental funds were allocated primarily for:

1

Upgrade waste gas treatment facilities

2

Tech Upgrades for Energy Saving & Carbon Reduction

3

Investments in clean production

4

Delivery of environmental training and awareness campaigns

## Environmental Risk Management

The Company enhances its environmental risk management capabilities, adhering to the principle of “Prevention First, Integrated Control, and Comprehensive Oversight.” It complies with the Environmental Protection Law of PRC and has established a lifecycle environmental risk management system, significantly bolstering its risk prevention and control abilities.

### Systems and Process Assurance

The Company has formulated 10+ specialized regulations to clarify environmental risk control responsibilities across departments and positions, ensuring compliance at all levels.


### Routine Compliance Audits

Regular self-assessments and audits are conducted, focusing on pollutant emissions, the operation of environmental facilities, compliance with EIA and the "Three Simultaneities" system, emergency response plan. Issue trackers are established to manage identified problems.

### Comprehensive Risk Prevention Measures

The Company identifies lifecycle environmental risks, categorizing and controlling risks in production processes and equipment operation. Preventive measures are implemented, supported by process optimization and upgrades to environmental facilities. Key control measures include:

Risk Type	Control Initiative	Result
Air Pollution Risk	Installed fume hoods at key positions and closed collection systems for VOCs; equipped with exhaust treatment.	Emissions exceed the "Integrated Emission Standard of Air Pollutants"; full compliance of fugitive emissions.
Noise Pollution Risk	Added soundproof enclosures for high-noise machinery; used sound-absorbing materials and optimized layout.	Boundary noise levels comply with standards, safeguarding employee and community health.
Water Pollution Risk	Established an integrated wastewater treatment system, discharging into municipal sewage.	Wastewater complies with the "Integrated Discharge Standard of Water Pollutants".
Solid Waste Pollution Risk	Created a regulated solid waste storage area; managed hazardous waste with proper labeling, transfer records and disposal by qualified organizations.	Solid waste disposal adheres to legal requirements; no risks of illegal dumping or leakage.



### Emergency Response Capacity Building

#### Emergency Response Plan System

The Company revised its "Emergency Response Plan for Environmental Incidents", outlining procedures and responsibilities for emergencies like gas leaks and wastewater exceedances. The plan is registered with environmental authorities and updated dynamically.


#### Practical Emergency Drills

In 2025, the Company organized emergency drills focusing on key environmental risk scenarios.

During the Reporting Period

**No** environmental violations occurred

**No** media exposures were recorded



## Pollution Prevention

Eyebright Medical prioritizes environmental protection and is not classified as a heavy polluter. The Company complies with the laws and regulations, integrating pollution prevention into all operations. It reduces emissions through environmental equipment installation and process improvements.

Qualified third-party organizations monitor wastewater, exhaust, and noise levels to ensure compliance with local standards, with all tests results during the Reporting Period met requirements.

During the Reporting Period

**No** major pollution incidents occurred within the Company or its subsidiaries

## Wastewater Management

The Company adheres to national and local standards, establishing a comprehensive wastewater management system that ensures effective environmental accountability through categorized collection, differentiated treatment, and compliant discharge.

During the Reporting Period

**All** treated wastewater indicators met national and local discharge standards  
**No** discharge exceedances or related environmental complaints occurred



### Facilities and Pipeline

Wastewater treatment facilities and standardized discharge points are established, with a separate drainage system to prevent cross-contamination.



### Treatment Processes

Treated production wastewater and filtered kitchen sewage flow into septic tanks before being discharged into the municipal sewer network.



### Rainwater Management

A rainwater retention system collects rainwater for irrigation, promoting resource reuse.

## Waste Gas Management

The Company adheres to the "Integrated Emission Standard of Air Pollutants" and ISO 14001 requirements, establishing a gas management system that includes source control, categorized collection, targeted treatment, and compliance monitoring to minimize atmospheric impact.

To ensure compliance, it employs various purification methods, such as activated carbon adsorption and advanced grease traps. Regular emissions monitoring conducted by professional organizations during the Reporting Period consistently met compliance standards.

### Case

#### VOCs and Exhaust Treatment

The Company has upgraded specific production zones by implementing workshop enclosure and installing fume hoods at operational points. This initiative has significantly reduced unorganized fugitive emissions. Process exhaust from production and exhaust generated during R&D activities are collected via dedicated ductwork and directed to specialized treatment units for purification, ensuring that final emissions comply with national air pollutant discharge standards.



During the Reporting Period

**All** exhaust indicators met compliance requirements

**No** emission exceedances or related complaints recorded

## Waste Management

The Company complies with the Law of PRC on the Prevention and Control of Environmental Pollution by Solid Wastes and the Regulations on the Administration of Medical Wastes, establishing a comprehensive waste management system that includes categorized collection, proper storage, compliant disposal, and source reduction to control environmental risks.

General solid waste includes material preparation scraps, waste packaging materials, and domestic waste that do not fall under the category of hazardous waste, is managed by qualified third-party organizations. Hazardous waste, including experimental liquids and reagent bottles, is strictly controlled and stored separately in specialized containers, with harmless disposal conducted by qualified third-party entities.

Regular training on hazardous waste management laws and disposal procedures ensures comprehensive control at all stages.

### Case

In 2025, the Company continued to focus on hazardous waste control by strengthening management measures to reduce ethanol consumption, minimizing hazardous waste generation at the source, and steadily advancing the implementation of waste reduction targets.



### Case

Since 2024, HiGenie has run an "Empty Tube Recycling" program for its single-use ampoules, encouraging consumers to participate in environmental protection through incentives like shopping credits and skincare products, thereby promoting the concept of sustainable development.



## Noise Management

The Company complies with the Emission Standards for Industrial Enterprises Noise at Boundary and ISO 14001 requirements, ensuring that boundary noise levels meet regulatory standards to minimize noise pollution and protect health. Furthermore, the Company optimally designs facility layouts and strategically plans production processes to effectively control noise generation at the source.

### Noise Reduction Measures

#### Fans and Air Compressors

- install professional silencers to reduce operational noise

#### Pumps and Fluid Transport Equipment

- Install soundproof walls and doors to minimize noise propagation

#### Production Equipment

- Soundproof enclosures are employed to contain equipment noise and prevent its propagation
- Advanced sound-absorbing materials and scientific techniques are applied to the operation room to reduce overall noise levels

## Resource Management

Eyebright Medical has strengthened its normalized resource governance, strictly applying the principles of reduction, reuse, and resource recovery at the operational level. By comprehensively enhancing resource efficiency, the Company leverages its innovative strengths to accelerate the implementation of circular economy models and green substitution strategies.

### Water Resources Management

The Company prioritizes the environmental impact of water consumption and actively focuses on conservation and efficient use. Regular monitoring is conducted for the identification of anomalies, enabling prompt analysis and targeted measures.

#### Water-Saving Measures

- Optimize landscape water usage based on actual demand
- Install water-efficient faucets with optimized flow rates to ensure rapid flushing and effective cleaning
- Display water conservation signage to raise employee awareness and encourage responsible usage
- Establish quarterly water consumption targets, regularly monitor and review usage data, and promptly formulate water-saving plans



### Energy Management

The Company actively promotes the systematic development of its energy management framework and has formulated institutional documents such as the Regulations on Energy and Energy Conservation Management. By driving diverse energy-saving initiatives, the Company continuously explores potential for reducing consumption, effectively curbs energy use, and enhances efficiency, thereby fostering a sustainable operational model centered on energy conservation and efficiency gains. In February 2025, the Company successfully obtained ISO 50001 Energy Management System certification.

## Energy-Saving Measures

### HVAC Efficiency

Implement variable frequency drives and energy-efficient designs

### Lighting Control

Use timed lighting for indoor areas and automatic controls for outdoor lighting based on natural light

### Smart Power Management

Establish an intelligent power management system for precise electricity control

## Case

### Eyebright Yantai Compressor Waste Heat Recovery Project

This project recovers waste heat from compressor circulating water. By industrial heat pumps, the return water temperature is raised to hot water boiler standards, integrating heated water into the supply system. This effectively reduces boiler startup loads and lowers gas consumption.

Since its launch, over 15 TJ of heat has been recovered and utilized.



## Green Production

Eyebright Medical employs advanced environmental technologies and equipment in its manufacturing processes, focusing on clean production principles of reduction, reuse, and recycling. The Company continually reduces energy consumption, water usage, and pollutant emissions, fostering harmony between the medical industry and the environment.

### Case

#### ✓ Optimized Process Operations

Enhanced drying processes to reduce solid waste and achieve cost savings

#### ✓ Automated Visual Verification

Developed automated systems for accurate information assessment, improving verification efficiency

#### ✓ Automated Packaging Line

Implemented upgrades to minimize waste generation during production

#### ✓ Automated Record Keeping

Automatically record testing data and generate electronic documents, enhancing efficiency and reducing paper use

#### ✓ Scanning Inventory System

Generate unique device identifiers (UDI) to improve inventory management and traceability

#### ✓ PDA Distribution System

Automate product scanning for outbound logistics, reducing errors and enabling automatic record archiving

#### ✓ Classified Recycling

Enforce "Categorized Collection, Dedicated Management, and Compliant Disposal" for hazardous waste, ensuring 100% disposal rates

#### ✓ Optimized Filter Consumables

Strengthen front-end dust control to reduce the load on primary and medium-efficiency filters, thereby decreasing filter replacement frequency and consumption

## Green Office Practices

Eyebright Medical promotes green office practices and eco-friendly commuting through digital, paperless operations to reduce resource waste and energy consumption. The Company fosters energy conservation awareness and a low-carbon culture in daily operations.

### Office Supplies Management

- Promote paperless operations
- Control printed materials
- Procure office supplies responsibly

### Electricity Management

- Implement energy-efficient lighting and on-demand controls
- Regulate air conditioning to minimize energy use
- Establish an energy inspection system to eliminate waste

### New Energy Vehicle Adoption

- Gradually replace company vehicles with new energy vehicles
- Encourage green commuting by providing public transport support for employees

### Green Environment

- Use low formaldehyde materials in office renovations to meet clean standards required for the medical device industry

## Climate Action

The Company recognizes the importance of proactive management in addressing physical and transition risks from global climate change. During the Reporting Period, the Company identified and assessed climate-related risks and opportunities, initiated climate resilience planning, and developed low-carbon transformation pathways aligned with its carbon neutrality goals.

The Board has incorporated climate change into long-term strategic planning as a key governance issue, defining our commitment to green development. The management team is implementing critical initiatives such as energy management system certification, low-carbon technology innovation in R&D, and production upgrades. The Company has also established emergency response plans and risk management mechanisms to enhance its climate governance framework and improve its capacity to manage environmental risks.

## Climate-Related Risks

This qualitative climate risk analysis is founded on the climate scenarios published by NGFS. To comprehensively evaluate risks, the Company selected the "NDC Scenario" within the "Hot House World" as high-emission, and the "Below 2 °C Scenario" within the "Orderly Transition" as low-emission. The assessment identifies flood risks caused by heavy rainfall and typhoons as the primary physical risks currently facing the Company. Based on the analysis, the Company has formulated corresponding risk mitigation measures. The Company will fully consider risk evolution trends under these climate scenarios, and strengthen safeguard measures to ensure climate-related impacts.

Risk Classification		Risk Characteristics	Potential Operational Impact	Potential Financial Impact	Risk Mitigation Measures
Physical Risks	Acute	Extreme weather risks (short to medium term)	Extreme weather events threaten supply chain stability, impacting product availability. Coastal facilities in Fujian Province and other regions are most severely impacted by typhoons and heavy rainfall.	Increased energy costs, operational disruptions, higher safety stock requirements, profit margin pressure.	Establish emergency response plans for environmental incidents; enhance disaster resilience of production facilities; properly allocate commercial insurance to mitigate economic losses from extreme weather.
	Chronic	Sea-level rise (irreversible risk)	Sea-level rise increases flooding risks in coastal areas.	Increased adaptation expenditures; asset impairment risk if flooding occurs.	Identify high-risk assets; implement national flood design standards in engineering projects.
Transition Risks	Policy and Regulation	Enhanced Energy Efficiency and Carbon Emission Assessments (Short to Medium Term)	Strengthened energy efficiency and carbon emission assessments under peak carbon policies.	Increased production costs, including capital expenditures for energy-saving upgrades and equipment renewal; short-term operational cost rises.	Closely monitor changes in international and domestic environmental and low-carbon regulations; comply with requirements to mitigate legal risks.
		Inclusion in Mandatory Carbon Emissions Trading Market (Short to Medium Term)	Inclusion in mandatory emissions trading schemes necessitates compliance with quotas, emission oversight and disclosure obligations.	Increased carbon costs and management expenses.	Install distributed PV systems to boost self-sufficiency in green power.
	Market	Enhanced green procurement preferences (medium to long term)	Enhanced green procurement preferences may raise focus on low-carbon attributes in bidding evaluations.	Insufficient green credentials may hinder market access, adversely affecting revenue and market share.	Continuously track market trends and customer demands; adjust business models and strategies accordingly.

		Rising consumer awareness of low-carbon impacts (medium term)	Rising consumer awareness of low-carbon impacts increases scrutiny on brand environmental responsibility	Poor management of brand environmental footprints may hinder sales growth and erode brand premium potential	Implement green actions; enhance green brand communication
	Technology	Pressure to enhance energy efficiency and upgrade production systems (Medium term)	The production process must enhance energy efficiency through upgrades, energy substitution, or process optimization to meet low-carbon emission standards	Increased capital expenditures due to equipment upgrades and technological modifications	Promote green production principles; optimize processes; bolster R&D in low-carbon technologies
		Continuous development of low-carbon processes and alternative materials (long term)	Continuous development of low-carbon processes and alternative materials may necessitate upgrades in production tech; inadequate reserves may lead to adaptation delays	Rising R&D expenses; lagging technology updates could affect long-term cost control	Increase R&D investment in low-carbon technologies; explore new alternative materials to reduce reliance on traditional high-carbon inputs
	Reputation	Insufficient climate disclosure or data accuracy concerns may raise "greenwashing" allegations	Incomplete or inaccurate disclosures could trigger regulatory scrutiny or media reports, damaging investor trust and market perception	Stock price volatility; potential brand damage affecting long- to medium-term sales and market valuation	Improve climate information disclosure; engage third-party verification for key carbon data; proactively address stakeholder concerns

## Climate Resilience and Adaptation

In response to escalating physical risks, the Company actively monitors industry trends, regulatory developments, and expert risk forecasts to anticipate climate threats. By enhancing local adaptation capabilities and optimizing emergency protocols, the Company can mitigate potential business interruptions and financial losses.

**Emergency Response**

The Company has identified key risk points and implemented targeted management. The Safety and Environment Department has developed emergency plans for extreme weather and conducts regular drills to ensure quick response, protect employees and assets, and restore operations promptly. Major production sites use dual power supply to maintain stable power for key equipment during maintenance or emergencies.

**Supply Chain Resilience**

The Company manages supply chain risks by maintaining safety stock and using multiple suppliers to avoid over-reliance. The Company only works with suppliers that meet environmental standards, which the Company verifies through on-site checks.

**Investment Decision-Making**

Climate resilience is embedded into our capital investment framework. During the feasibility stage for new or expanded projects, the Company assesses historical climate data to optimize site selection, design standards, and construction specifications, ensuring long-term business sustainability.

To address policy, market, and technology-related transition risks, the Company implements the following strategies:

**Energy and Carbon Management**

Through robust energy management systems and efficiency upgrades, the Company reduces fossil fuel dependence to minimize future compliance costs associated with carbon pricing and taxation.

**Operational Optimization**

The Company promotes green practices across offices and production sites to lower resource consumption and emissions, aligning with increasingly stringent regulatory requirements.

**Low-Carbon R&D**

The Company innovation process integrates energy efficiency, material recyclability, and lifecycle environmental impact assessments. This drives technological advancements that mitigate transition risks and unlock new market opportunities.

**Environmental Management System**

The Company continuously maintains ISO14001 certification to institutionalize environmental governance, ensuring agile policy response and compliant operations.

## Greenhouse Gas Emissions

The Company conducted a comprehensive annual greenhouse gas inventory, adopting the operational control approach in accordance with the General Guideline of the “Greenhouse Gas Emissions Accounting and Reporting for Industrial Enterprises” (GB/T 32150) and the “Greenhouse Gas Protocol: Corporate Accounting and Reporting Standard”.

This inventory established the Company's emissions baseline, pinpointing core hotspots and decarbonization levers. Building on this baseline, the Company has systematically quantified climate risks, set science-based emission reduction targets, and formulated specific adaptation measures and transition roadmaps.

Greenhouse Gas Emissions	Unit	2025
<b>Scope 1</b>	<b>ktCO<sub>2</sub>e</b>	<b>2.68</b>
Fossil Fuel Combustion	ktCO <sub>2</sub> e	1.42
Direct Fugitive Emissions	ktCO <sub>2</sub> e	1.26
<b>Scope 2</b>	<b>ktCO<sub>2</sub>e</b>	<b>28.74</b>
Electricity	ktCO <sub>2</sub> e	27.78
Heat	ktCO <sub>2</sub> e	0.96
<b>Total Emissions (Scope 1 + Scope 2)</b>	<b>ktCO<sub>2</sub>e</b>	<b>31.42</b>

Notes:

1.Scope 1 Emissions encompass direct emissions from stationary fossil fuel combustion (Natural Gas, LPG), mobile source combustion (Gasoline, Diesel), refrigerant fugitive emissions, and wastewater treatment. Emission factors for fossil fuels reference the IPCC Guidelines for National Greenhouse Gas Inventories and China National Greenhouse Gas Emission Factor Database; methane factors for industrial wastewater reference the latter.

2.Scope 2 Emissions comprise indirect emissions from purchased electricity and heat. The electricity emission factor references the “2023 National Average CO<sub>2</sub> Emission Factor for Electricity” issued by China’s Ministry of Ecology and Environment.

## Ecosystem and Biodiversity Protection

Eyebright Medical adheres to environmental protection laws, including the “Forest Law of PRC and Law of PRC on Water and Soil Conservation”. The Company uses resilient, low-maintenance plants to create diverse green landscapes that improve local microclimates and protect biodiversity. A rainwater collection system further reduces runoff pollution and provides recycled water for irrigation.

Through these ecological initiatives, the Company fosters a sustainable ecosystem that enhances ecological value and creates a quality green workspace for employees.

# Social

Eyebright Medical actively fulfills its corporate social responsibility by prioritizing research and innovation, promoting academic exchange, and ensuring stringent product quality while optimizing the supply chain for sustainable value chain development. The Company values employee growth and is committed to providing a robust career development platform. Additionally, it actively participates in social welfare activities, leveraging its resources and capabilities to enhance public health and contribute positively to society.



# Innovation-Driven

Eyebright Medical prioritizes innovation as the cornerstone of high-quality development. In ophthalmology medicine, it accelerates research and development (R&D) initiatives, strengthens its talent pool, and creates a comprehensive industry-university-research platform, thereby establishing a solid mechanism to support scientific innovation.

## Scientific Research Framework


The Company has refined its R&D management policies and improved its innovation capacity. The Company utilizes a project leader system wherein the leader oversees the entire product development process, from initiation to post-market feedback. This structure enhances collaboration and increases product development success rates.

To enhance R&D efficiency and quality, Eyebright Medical builds a high-caliber research team through a regular training regimen that focuses on advanced knowledge, standardized procedures, and compliance with industry regulations, thus ensuring effective project execution and quality control.



## R&D Investment

Technical innovation is vital for maintaining Eyebright Medical's core competitiveness. The Company emphasizes cutting-edge technology and consistently allocates a significant portion of its resources to R&D, thereby enhancing innovation and efficiency to support its strategic objectives.



## Recently Introduced Products


China



The First Aspherical Phakic Intraocular Lens in China, The Loong Crystal™



Proming® Extended Depth of Focus intraocular lens



Non-Refractive Rigid Gas Permeable Contact Lens for Orthokeratology (NORW)



Contact Lens Care Solutions



iBright® AI Digital Fitting System



Upgraded Designs for Multiple Defocus Frame Glasses



7 models of Soft Hydrophilic Contact Lenses

## Overseas



- Monofocal and Extended Depth of Focus intraocular lenses received MDR CE technical assessment certificates
- Multiple preloaded intraocular lens products gained regulatory approval in Malaysia, Vietnam, Peru, and other countries along the Belt and Road
- Successfully completed on-site quality system audits by regulatory authorities in Korea and other regions
- Obtained listing certificates from the Hong Kong Department of Health's Medical Device Division for various products, including the phakic intraocular lens, a full range of intraocular lenses, and orthokeratology lenses

## Intellectual Property Protection

Eyebright Medical complies with national innovation strategies and relevant laws, such as the Patent Law and Copyright Law of PRC. The Company has established robust mechanisms for patent and copyright protection, implementing internal guidelines to promote the recognition and commercialization of patents, thereby enhancing its intellectual property management capabilities.


During the Reporting Period

 **61**  
 Patents Applied

 **41**  
 Patents Granted

As of December 31, 2025


 **480**  
 Total patents applied

 **291**  
 Total authorized and valid patents

International patents cover regions including Europe, the United States, Japan, South Korea, and Singapore

## Experimental Ethics

The Company rigorously complies with welfare and ethical review standards in animal experiments.



All commissioned animal studies are conducted by certified third-party institutions that meet AAALAC standards. Ethical governance is a key admission criterion, requiring the establishment of an Independent Animal Care and Use Committee (IACUC) for mandatory review and oversight.



# Collaborative Industry Advancement

Eyebright Medical actively fosters domestic and international academic exchanges, establishing a global platform that integrates medical research with clinical practice. The Company participates in industry standards development and collaborates with universities to cultivate ophthalmic talent, thereby advancing innovation in ophthalmic care.

## Academic Exchange

The Company recognizes collaboration as essential for technological innovation and has engaged in numerous academic activities to create a comprehensive exchange platform. By organizing and attending forums and seminars, it collaborates with experts to explore cutting-edge technologies and address key academic challenges.

In 2025, Eyebright Medical participated in major conferences, including Congress of Chinese Ophthalmological Society (CCOS) and Vision China 2025, showcasing its innovations at international events such as ESCRS and IOC, and gaining recognition for its advanced technologies.



During the Reporting Period

- 
2  
 International Exhibitions
- 
18  
 National Conferences
- 
43  
 Regional Meetings
- 
65  
 Self-hosted Meetings
- 
1,400+  
 Online Participants
- 
10,000  
 Online Total Views
- 
1,700+ minutes  
 Online Viewing Time

Case

### Clinical Application Sharing of Bifocal Intraocular Lens

This regional academic exchange promotes bifocal intraocular lens, engaging nearly 600 clinicians across 15 provinces in China, breaking geographical barriers in ophthalmic technology.



### COE Center Launch

The Company established the "Cataract Surgery Demonstration Center" in partnership with medical institutions. This event involved nearly 100 professionals, promoting standardized treatment for cataract.



### Advanced Training Camp for Refractive Multifocal Intraocular Lens

This online camp addresses complex cases like high myopia, providing targeted training for KOLs in public and private institutions to enhance product application skills.



### Myopia Management Investigation Journey

Now in its fifth year, this event has attracted over 800 clinical practitioners, establishing itself as a brand-driven academic benchmark.

The 2025 competition covers six major regions with 11 events, fostering a continuous platform for learning, exchange, and growth through a "fixed team, annual points, ultimate showdown" format.



### Myopia Prevention and Control Seminar with IAOA Training

Collaborating with IAOA, the Company hosted foundational training that integrates theory and practice, receiving high praise with eight sessions conducted in 2025.



Case



Clinical Symposium on iBright® Defocus Frame Lens

The iBright® series has garnered positive feedback since its launch. Several clinical symposiums were held to support effective myopia prevention in children and adolescents.



Domestic Intraocular Phakic Lens Application Summit

Following the launch of the Loong Crystal™, whose technology has broken the imported dominance. To standardize the clinical application, the Company organized multiple Summit Seminars for the "Domestic Intraocular Lens Clinical Application" throughout the year, covering around 200 surgeons.

## Standard Establishment

High standards are crucial for driving quality development. Corporate standards underpin innovation, technical capacity, production efficiency, and social responsibility, while facilitating communication and trust among enterprises, clients, partners, and the public. Eyebright Medical actively participates in the standardization of medical devices to promote high-quality industry development.

In 2025, the Company joined the ISO/TC172/SC7 International Organization for Standardization for Ophthalmic Optics and Instruments, contributing to the drafting and revision of various national and industry standards. These efforts cover areas such as intraocular lenses, frames, and corneal reshaping lenses, reinforcing the advancement of the industry.

Standard Name	Participation
T/CI 1363-2025 Code of Application for Spectacles in Myopia Management Related to Myopia Prevention and Control	Participation in Drafting
GB 11417.2-2025 Ophthalmic Optics - Contact Lens - Part 2: Rigid Contact Lens	In Revision and Validation
GB 11417.3-2025 Ophthalmic Optics - Contact Lens - Part 3: Soft Contact Lens	In Revision and Validation

## School-Enterprise Cooperation

### iBright® Spark Program

Eyebright Medical's "iBright® Spark Program " enhances R&D and talent cultivation through school-enterprise collaboration. By sharing resources and developing joint curricula, it creates training bases that integrate education with industry, improving talent quality and efficiency to meet market demands and support industry growth.



During the Reporting Period

¥ RMB **700,000** in materials Donated over

👤 **2,000+** students Benefited

🕒 **188** Training Hours

Since 2022

🏢 Collaborated **16** universities


📍 Extended **13** provinces

¥ Donated over RMB **5.3** million in materials

🕒 **700** training hours

👤 Empowered **4,500+** students

👤 Benefited **15,000+** professionals




## Training & Empowerment

### Three Major Training Centers for Orthokeratology Lens

Eyebright Medical collaborates with renowned ophthalmic hospitals and industry associations to establish three training bases in China Eye Valley, Tianjin Eye Hospital Optometric Center, and its Beijing headquarters. These bases offer a comprehensive learning platform for vision care practitioners, focusing on standardized fitting of orthokeratology lenses and myopia prevention.

To address the industry's demand for interdisciplinary talent, Eyebright Medical initiated the first management empowerment class for optical centers in 2025 at Tianjin Eye Hospital's Optometric Center teaching base. The class employs a "Technology + Management" dual-core model, focusing on digital system development, customer management, and talent cultivation, thereby enhancing the skills and operational management capabilities of participants.



During the Reporting Period

**3** training sessions

**80+** training hours

**110+** attendees

Since 2021

**30+** provinces and regions

**400+** hospitals and optical centers

**650+** industry professionals

### Cataract Phacoemulsification Training Center

Eyebright Medical established a cataract surgical training platform for phacoemulsification, providing year-round training for hospital doctors at major hospitals.



In 2025, it delivered **3** phacoemulsification training sessions, supported **40+** clinicians, and hosted **130+** physicians from **70+** hospitals—including participants from Belt and Road Initiative countries—while providing equipment and venue support for in-hospital training.

### Loong Crystal™ PR Certification Training

At the beginning of 2025, the Loong Crystal™ PR Phakic Intraocular lens, the nation's first aspheric phakic intraocular lens, was launched. To effectively standardize the clinical application and market promotion of this product, Eyebright Medical implemented extensive and systematic training.

Conducting **11** doctor certification training sessions throughout the year.  
Holding **360+** clinical department training meetings.



### IBRIGHTELITE Youth Paper Award

Founded in 2021, the IBRIGHTELITE Youth Paper Award, in collaboration with Vision China, encourages young ophthalmologists, vision care practitioners, and students to explore the fields of ophthalmology and visual health. It promotes academic exchange and innovation, fostering the growth of future leaders in the eye care industry.



During the Reporting Period



**4** recipients  
Premier Paper Award  
(Best Winner)



**8** recipients  
Excellence Paper Award



**14** recipients  
Outstanding Paper Award



**42** recipients  
Popular Paper Award



**32** recipients  
Excellent Poster Award



**100** recipients  
Supported

Since 2021



**334**  
Total Young Scholars Funded

## Accessibility of Medical Services

Eyebright Medical emphasizes value creation, striving to offer high-quality, accessible eye health services. The Company integrates intelligent solutions, including artificial intelligence, to enhance the quality and availability of ophthalmic care, ensuring equitable and efficient services for underserved populations.



### Promotion of 24-Hour Smart Contact Lens Stores

Eyebright Medical's 24-hour smart contact lens store project has been recognized in the "2025 Key Application Scenario Support Project List" for its innovative use of embodied intelligence. Successfully launched in cities like Beijing, Shanghai, Guangzhou, Shenzhen, Chongqing, and Hangzhou, these stores utilize humanoid robots to enhance customer service. The Company is committed to expanding this initiative nationwide.



### Eyebright Medical Eye Health Education Center continues to run Professional Program

Eyebright Medical addresses key public health issues, including cataract prevention for the elderly and myopia control for children and adolescents. The Company has developed a hybrid online and offline education system, collaborating with professionals to provide accessible eye health information. This initiative promotes proactive prevention among students, parents, and seniors, enhancing the reach and sustainability of eye health services. It aligns with the national goal of universal access to basic ophthalmic care, offering a replicable model for "Healthy China".



# Product Responsibility

Eyebright Medical views product quality as critical to its operations, adhering to strict safety standards and developing a sustainable supply chain. The Company optimizes its customer service to ensure that every phase, from raw material procurement to delivery, meets the highest industry standards.

## Quality Management

Eyebright Medical enhances its quality and safety management systems through a focus on organizational structure, compliance, supervision, and training. This commitment ensures effective control over product quality and safety, protecting patient health.

### Quality Management System

Building upon the ISO9001 standard, the Company aligns its operations with a comprehensive framework of domestic and international regulations, including ISO13485, the EU MDR, and GMP requirements for Korea and Brazil (RDC665/2022). The Company continuously refines its organizational, institutional, and supervisory frameworks by embedding quality risk management and control directly into its business processes. Through the rigorous implementation of quality objectives and active engagement with global regulators and third-party auditors, the Company ensures the robust and reliable operation of its Quality Management System.

ISO9001	ISO13485	KGMP
GB/T42061	RDC	GMP
EU MDR	CE Certificate	Medical Device License

**During the Reporting Period**  
 The company underwent **20** external audits **all** passed on the first attempt, recorded **no** significant product quality incidents, and had **seven** products subject to national-level sampling inspections with qualified results.

Eyebright Medical's CNAS testing center is accredited by the China National Accreditation Service for Conformity Assessment (CNAS), making it the first private laboratory in China for intraocular lenses to achieve this recognition. Equipped with advanced testing equipment, the center ensures robust support for product quality and safety.

In December 2025, the Company contributed to the release of the "Guidelines for Internal Risk Communication and Discussion on Quality and Safety of Medical Device Manufacturers" under the ZGC Medical Devices Innovation Alliance, underscoring its expertise in quality management.



## Quality and Safety Control

The Company has implemented a "Risk Management Control Procedure" to systematically identify, analyze, evaluate, and control product safety risks. Regular assessments refine this process, ensuring regulatory oversight across all stages of product R&D, production, and materials management to maintain consistent and reliable product quality.



During the Reporting Period

**NO** product safety or health-related recalls

## Quality Safety Training

Eyebright Medical emphasizes the enhancement of employee quality awareness and skills as a central aspect of quality management. The Company offers targeted quality safety training, covering professional knowledge, operational standards, legal regulations, industry standards, internal controls, ethics, and case studies. This systematic training strengthens employees' understanding and practical skills, establishing a solid foundation for quality control and supporting sustainable growth.



## Customer Service

The capability and quality of service are central to competitive advantage. Eyebright Medical is committed to a customer-oriented approach and responsible marketing principles. The Company has established comprehensive service management systems, including the "Service Control Procedure" and the "Customer Feedback and Complaint Control Procedure", to actively incorporate feedback and enhance clients experience.



The Company conducts biannual in-depth customer satisfaction surveys to identify potential issues, allowing for targeted improvements, confirming its commitment to continuous quality enhancement.

Case

Customer Satisfaction Survey  
Average score: above 9.8

In 2025, the Company conducted satisfaction surveys with agents and direct-selling hospitals, assessing product usability, effectiveness, and delivery processes. Participants reported an overall average score exceeding 9.8, indicating high satisfaction with the Company's products.


During the Reporting Period

**NO** significant customer complaints

## Sustainable Supply Chain

### Supplier Management

Eyebright Medical prioritizes supplier management as an extension of its corporate values, guided by three principles, including Strict Selection of Quality Suppliers, Long-term Strategic Partnerships and Social Responsibility and Environmental Awareness.

	<p><b>Tiered Management</b></p>	<p>The Company implements a "Procurement Control Procedure" to categorize suppliers and materials into ABC tiers based on risk, qualifications, and quality, enabling dynamic evaluations.</p>
	<p><b>Evaluation System</b></p>	<p>The Company maintains a record of qualified suppliers, prioritizing those with ISO14001, ISO45001, and ISO50001 certifications to enhance environmental and safety management.</p>
	<p><b>On-site Inspections</b></p>	<p>The Company's "Key Supplier On-site Inspection System" assesses critical suppliers' environments, quality systems, and delivery capabilities.</p>

### Responsible Procurement



The Company formalizes demand planning and supplier agreements, including a "Medical Device Quality Assurance Agreement" that specifies liability and risk notification clauses to ensure product quality.

During the Reporting Period

**NO** incidents of returned goods due to procurement inspection issues were reported

# Employee Development


Eyebright Medical considers its employees the most valuable asset, upholding a culture of innovation, openness and harmony, honesty, and sharing success. Committed to fostering a diverse workplace, the Company provides opportunities for employees to demonstrate their talents and enhance creativity, aligning individual aspirations with corporate objectives.

## Employees Rights and Interests

### Compliance with Employment Regulations

Eyebright Medical adheres to principles of equality and inclusivity in hiring, strictly following the Labor Law of PRC and related regulations. Clear processes are established to ensure fairness and protect the rights of employees and candidates.

The Company employs a diverse recruitment strategy, including online platforms, campus recruitment, and internal referrals to attract top talent. To encourage employee involvement, the "Bole Award" is offered to reward successful talent referrals, fostering a robust talent acquisition ecosystem.



## Inclusive Workplace

Eyebright Medical is dedicated to fairness in recruitment, training, and promotion, ensuring equal treatment for employees of diverse backgrounds, including region, ethnicity, age, gender, religion, and culture.

The Company prioritizes the protection of women’s rights, adhering to relevant laws to provide equitable opportunities and career development. Eyebright Medical actively fosters a supportive environment for women’s professional growth.

In alignment with government initiatives promoting employment for individuals with disabilities, Eyebright Medical offers tailored job opportunities and benefits, fulfilling its social responsibility. By 2025, the Company has provided job positions for five individuals with disabilities.

Percentage of Female Executive



As of the end of the Reporting Period

Female executives accounted for **50%** of the total

## Cultivation and Development

### Compensation and Incentives

Eyebright Medical recognizes employee motivation as essential for sustained growth. The Company has established a comprehensive compensation system, including salaries, performance bonuses, and equity options, to enhance engagement and loyalty.

In 2025, the Company strictly followed legal requirements and board resolutions, implementing equity incentives under the 2021 Restricted Stock Incentive Plan for eligible employees, thereby fostering innovation and shared growth.

During the Reporting Period

**77** employees received stock allocations totaling **265,032** shares



## Promotion Mechanism

Eyebright Medical values employees and uses a dual-track promotion system to meet business needs and provide clear career paths. The Company promotes a culture of efficient, fair performance, using a performance management system aligned with business goals, measuring both company achievements and individual contributions.

In 2025, the Company assigned employees to roles in subsidiaries, strengthening management and technical capabilities and promoting cultural integration.

 Key Performance Indicators

 Work Attitudes  Work Plans

## Talent Development

Eyebright Medical prioritizes employee skills development and career growth. Training is central to its HR strategy, following "empowering employee growth to support strategic implementation." With integrated resources and a dual-driven system, it ensures continuous learning and improvement, creating a positive learning culture.

Headquarters  
Training in  
2025

 **224**  
Total training sessions

 **17,536**  
Total training hours

 **5,269**  
Total participants

### Leadership Training

#### Peking University Economic Management Training Program

The Peking University Economic Management Training Program ran from August 2024 to July 2025, empowering managers and receiving positive feedback. The second phase began in October 2025 for mid-level leaders and key client personnel, strengthening managerial capabilities and promoting partner collaboration.



#### Business and Management Synergy

By emphasizing "knowledge extraction, contextual transformation, and precise empowerment", this initiative, the program has received broad approval from participants, promoting individual capabilities, team collaboration, and organizational development, thus strengthening the Company's production system and core competitiveness.



### Expert Lecture Series



In 2025, the Company launched the Expert Lecture Series, conducting 12 in-person training sessions throughout the year. These sessions integrate market insights, customer needs, and technological development. This initiative enhances the industry perspective and business acumen of R&D personnel, aligning technology with market demands. Furthermore, it fosters departmental collaboration and encourages cross-disciplinary innovation, supporting the Company's sustainable development.

### General Skills Training



In 2025, the Company provided ongoing general skills training on onboarding, digital capabilities, collaboration, and compliance. This helped employees grow comprehensively and strengthened the Company's talent foundation.

### Professional Skills Training



Targeted training in lean production and quality management tools was provided, improving the capabilities and efficiency of staff.

### Internal Knowledge Sharing

The Company emphasizes the importance of knowledge management and experience sharing. A group of internal trainers has been developed to share expertise on new product launches, legal fundamentals, and tax knowledge, promoting effective information flow and ensuring operational efficiency.



### New Employee Onboarding Training

During the Reporting Period, the Company organized regular onboarding training for new employees to convey corporate culture and behavioral guidelines. This program fosters a sense of belonging and identity, facilitating the transition from industry newcomers to valued members of the corporate community. The training is designed with a focus on "cognitive empowerment and emotional cohesion", addressing strategic awareness, role clarification, cultural alignment, and team bonding, thereby laying a solid foundation for mutual growth.



## Welfare and Care

### Employee Benefits


The Company prioritizes employee health management by adhering to legal requirements and offering additional benefits such as supplementary medical insurance, health check-ups, annual leave, holiday gifts, and Beijing residency permits. These diverse welfare measures enhance employee development, well-being, and overall sense of belonging.

<b>Statutory Benefits</b>	<ul style="list-style-type: none"> <li>○ Pension insurance, work injury insurance, unemployment insurance, maternity insurance, medical insurance</li> <li>○ Housing provident fund</li> <li>○ Statutory holidays and paid leave</li> </ul>
---------------------------	---

<b>Company Benefits</b>	<ul style="list-style-type: none"> <li>○ Supplemental medical insurance, annual health checkups, specific disease screening for female employees, care leave for female employees</li> <li>○ Employee assistance program (EAP)</li> <li>○ Beijing residency permits</li> <li>○ Meal subsidies, holiday gifts, special allowances</li> <li>○ Free shuttle service, nursing facilities, gym, basketball court, and cafeteria</li> <li>○ Awards for innovation, patents, outstanding performance, and distinguished contributions</li> </ul>
-------------------------	---

### Democratic Communication

The Company values employee feedback and promotes an open communication culture. It utilizes various channels to understand employee needs and has an internal information-sharing system for timely responses. Continuous process optimization and work environment improvements enhance employee satisfaction and foster a positive corporate culture.


Multi-Channel Communication Mechanisms

- ★ Employee Congress & Executive Committee: Regular meetings and proposal systems to safeguard and oversee employee rights
- ★ Management Feedback Mechanism: Employee input is solicited at annual R&D, sales, operational and management meetings
- ★ Employee Relations Specialists: Manage communication channels, provide labor coordination and career planning support
- ★ Executive & Audit Visits: Multi-level engagement to collect employee feedback
- ★ Internal Company Journal: Highlight employee accomplishments and foster internal culture sharing

## Work-Life Balance

The Company prioritizes work-life balance by creating an employee-centered support system that addresses diverse needs. It organizes various activities to enrich employees' cultural and spiritual lives, promoting balance between work and personal life.



### Create a "diverse and friendly" workplace environment.

To meet diverse needs, the Company has established a nursing room for breastfeeding mothers, built basketball courts and gyms for fitness enthusiasts, and provided shuttle services covering major residential areas and transport hubs to ease commuting.



### Case


#### World Book Day Events

For the fourth years, Eyebright has celebrated World Book Day by gifting books to employees' children, promoting core values and fostering a love for reading among over 350 families.



#### Sport Events

The second Sport Day featured nearly 40 matches, promoting physical fitness and enhancing interdepartmental collaboration.



Case

### Fifth Employee Photography Contest

Themed "Pictures of Light, Dreams in Vision ", the contest received nearly a thousand entries, showcasing the beauty of Eyebright and life, contributing to the Company's legacy for 2025.



### 15<sup>th</sup> Anniversary Celebration

All employees reflected on 15 years of achievements and envisioned a bright future, enhancing team cohesion. All employees gathered to celebrate our achievements, look ahead with confidence, and mark this milestone as we begin a new journey for the next 15 years.



### 2025 Team-Building Trip

The Huzhou excursion was designed to strengthen collaboration and provide employees with an opportunity to relax and connect.



### Sales Department Family Day

The Company's Marketing Department hosts annual Family Day events to strengthen team cohesion and bridge the gap between work and home. These activities offer families a glimpse into our corporate culture, fostering a harmonious and supportive work environment through engaging interactions.



## Subsidiary Activities Highlights



Annual Conference & 10<sup>th</sup> Anniversary Celebration




International Women's Day Floral Workshop



Fun Sports Day Team Building



Qixi Festival Lacquer Fan Workshop



Badminton Tournament



Dragon Boat Festival Celebration



Lantern Festival Crafting Workshop



Team-Building Trip to Linyi



Mid-Autumn Festival Garden Party

## Occupational Health and Safety

### Occupational Health and Safety

Eyebright Medical is committed to employee health and safety, adhering to national and international regulations, including the Work Safety Law of PRC and achieved ISO45001 Occupational Health and Safety Management System certification. It continuously invests in resources to enhance safety management and provide a secure work environment.



During the Reporting Period

**NO** safety or occupational health incidents occurred.

### Safety Production

Eyebright Medical strictly implements the safety production policy of "Safety First, Prevention Foremost, and Comprehensive Governance". By reinforcing safety responsibilities and standardizing management practices, the Company has elevated its overall safety performance, effectively mitigating production accidents and occupational diseases to ensure sustainable growth. Eyebright Medical has achieved Level 3 Work Safety Standardization Certificate.



Safety First



Prevention Foremost



Comprehensive Governance

The Company prioritizes safety education, conducting regular training on production safety, fire prevention, and emergency evacuation to enhance employee safety awareness and proficiency.



### Emergency Management

To standardize emergency responses, the Company has established a Work Safety Incident Emergency Plan comprising comprehensive, specialized, and on-site protocols. Supported by dedicated emergency supplies, regular drills in fire, chemical, and biological safety are conducted to enhance employee readiness and minimize potential losses.

## Serve the Society

Enterprises play a vital role in society, and serving community needs is their duty. Eyebright Medical integrates social responsibility into its development strategy, actively engaging in philanthropy and rural revitalization initiatives, and aspires to be a model of humanistic care and social commitment.

### Rural Revitalization

While advancing core business, the Company upholds a long-term vision to support rural revitalization, prioritizing improvements in infrastructure, basic livelihood security, and the cultivation of specialty industries.

#### Partnership for Rural Revitalization

In 2025, the Company supported rural revitalization in Ar Horqin Banner, Inner Mongolia, by pairing with three villages and funding key infrastructure projects including agricultural storage, feed equipment maintenance, and community greening.

#### Road Improvement Initiative

In 2025, the Company donated funds to the villagers' committee of Xiayuan Village, Leping Town, Pingba District, Anshun, Guizhou, to support the road widening and upgrade project. The donation aims to improve transportation infrastructure and help fully resolve residents' travel difficulties.



## International Aid Initiatives

Eyebright Medical is dedicated to advancing global eye health through the "Belt and Road" international cooperation. The Company provides high-end ophthalmic devices, including intraocular lenses and injectors, for the "Guangming Xing" (Light Journey) missions.

Eyebright Medical collaborated with Chinese medical teams on "Belt and Road" projects across Morocco, Fiji, Cambodia, Equatorial Guinea, Uzbekistan, Kyrgyzstan, and Ethiopia. By providing domestically developed premium products—including IOLs, viscoelastic, and surgical blades—the Company enabled patients to regain clear vision, contributing to the building of a global community of health for all.



## Medical Donation

Aligning with the "Healthy China" strategy, Eyebright Medical leverages its strengths to conduct grassroots medical aid initiatives, donating intraocular lenses and surgical supplies to underserved patients in remote areas, thereby consolidating rural revitalization achievements.


Throughout the Reporting Period, the Company donated surgical supplies including intraocular lenses, viscoelastic, and surgical blades, as well as reading glasses to multiple regions, including Qinghai, Jilin, Ningxia, Yunnan, Tibet, Gansu, Shanxi, Sichuan, Xinjiang, Henan and Hainan, bringing hope and light to patients in need.



## Public Welfare and Charity

### Eyebright Growth Partnership Series

In celebration of International Children's Day, Eyebright Medical, in collaboration with the China Charity Federation, hosted the "Eyebright Accompanies Your Growth" event at the Central Primary School in Madian Town, Henan, providing care packages and holiday wishes to students



Eyebright Medical conducted the "Illuminating Vision with Love" charity event at the Xiaojudeng Children's Rehabilitation Education Center in Beijing, celebrating Mid-Autumn Festival with children by offering warm greetings and companionship.



Prior to New Year's Day, Eyebright Medical held the "Illuminating Vision with Love" New Year charity event at the Huicongshu Children's Rehabilitation Institute and RY Community Learning Center, delivering essential supplies and engaging children in festive activities.



## Support for Overseas Chinese

Before the Dragon Boat Festival, Eyebright Medical partnered with the Beijing Overseas Chinese Service Center for the "Fragrant Zongzi and Patriotic Heart" initiative, providing care packages and greetings to elderly overseas Chinese community members.



Before the Double Ninth Festival, Eyebright Medical collaborated with the Beijing Overseas Chinese Service Center to offer eye health education and sent warm wishes to elderly members of the community.



Eyebright Medical donated funds to the Beijing Overseas Chinese Charity Foundation to support the closing cultural exchange event on Overseas Chinese Modernization, advancing cultural programs for the overseas Chinese community.



## Elder Care Initiatives

Eyebright Medical donated to the Shanghai Charity Foundation's "Filial Piety and Elder Care" program. This funding empowers medical teams to deliver authoritative TCM knowledge directly to seniors, demonstrating its deep commitment to elderly care.



## Firefighter Greetings Activity

Eyebright Medical paid a visit to the Fire and Rescue Brigade of Ganyu District, Lianyungang City, Jiangsu Province. The Company extended festive greetings and gifts to all firefighters and commanders who have long been dedicated to emergency rescue and safeguarding public safety, expressing high respect and heartfelt thanks for their selfless contribution.



## Scientific Popularization

### Eyebright Growth Partnership Series

#### Back-to-School Eye Care Open Day

During the Reporting Period, Eyebright Medical initiated the 2025 Back-to-School Eye Care event at its Beijing headquarters. Guided by the Beijing Municipal Medical Products Administration's Fourth Division, the program engaged multiple families of iBright® users.

Professor Yu Jifeng from the National Children's Medical Center presented a lecture, while R&D scientists outlined the principles for selecting myopia prevention products for children, highlighting the importance of individualized approaches under professional supervision.



#### New Year Vision Helath

Eyebright Medical organized the "Welcoming the New Year-Eye Health Awareness" event, inviting children and adolescents to the Company for educational lectures, vision tests, and discussions on corrective lens experiences.



### Community Outreach Program

To enhance community ophthalmic health and reduce the incidence of blindness-causing diseases, Eyebright Medical partnered with ophthalmology experts from Changping District Hospital. This initiative, held in the Huojiaying community, featured educational lectures, cataract screenings, and myopia prevention efforts, offering residents valuable eye health information at their doorstep.



### Community Outreach Program

On National Sight Day, Eyebright Medical hosted the "Healthy Eyes Foster a Bright Future" outreach at School of Economics and Management, Tsinghua University. By translating cutting-edge ophthalmic insights into actionable care, the initiative empowered faculty and staff with enhanced awareness and scientific eye protection skills.



### Community Outreach Program

In response to the Ministry of Science and Technology and local authorities, Eyebright Medical established an educational e-station at Nanshao Central Primary School in Changping District, promoting scientific literacy and awareness through engaging activities.



# Governance

Eyebright Medical strictly complies with relevant laws, regulations, and normative guidelines to advance corporate governance. The Company continuously improves its governance structure, standardizes internal controls and risk management mechanisms, protects the rights of shareholders and investors, upholds business ethics, and prioritizes information security and privacy protection to safeguard high-quality development.




# Corporate Governance

Leveraging a robust corporate governance structure and operating mechanisms, Eyebright Medical actively builds a scientific, efficient, and forward-looking governance system. The Company continuously advances compliance management, and enhances its ability to manage and operate in accordance with the law. It increases transparency in communication with the capital market to foster mutual trust and long-term value growth.

## Governance Structure

In accordance with the Company Law, Securities Law of PRC, and Rules Governing the Listing of Stocks on the STAR Market of the Shanghai Stock Exchange, the Company maintains a robust internal governance framework comprising the General Meeting of Shareholders, Board of Directors, and Senior Management.

During the Reporting Period, the Board consisted of nine members, including six Non-Independent Directors and three Independent Directors. The Board oversees business operations, strategic planning, and internal organizational structure. It is supported by four specialized committees: the Audit Committee, Strategy Committee, Compensation and Assessment Committee, and Nomination Committee. All Board and committee members possess relevant industry experience and professional knowledge, regularly participating in diverse training programs to enhance their competencies.



## Board and Management Operations

### Independence

The Company continuously improves its modern management mechanism. During the Reporting Period, it revised internal control systems. The Company also formulated the Independent Director Work System. Independent Directors are required to submit the Self-inspection Report to the Board, ensuring that independent directors meet requirements for "independence".

### Specialization

The Board of Directors has set up four special committees. Members maintain rigorous meeting attendance, engage in systematic review of management reports, and conduct robust oversight through critical evaluation processes. Their structured advisory input ensures Board deliberations incorporate multidimensional expertise, thereby enhancing decision-making quality and governance efficacy.

### Diversity

The Company is committed to Board diversity. In se diversified criteria-including professional qualificati meet enterprise development needs. Board membe recommendations that enhance the Company's go

#### During the Reporting Period

Female members accounted for **33.3%** of the Board.

The senior management team covers professional fields such as materials science, optics, sales and financial accounting, and has rich experience in R&D, operation management, financial management and other aspects.

#### During the Reporting Period

Female members accounted for **50%** of senior management.

### Enhancement of Competency

The Company regularly organizes Directors and Senior Management to participate in training hosted by regulatory authorities and industry associations.

#### During the Reporting Period

Board members participated in over **20** training sessions.

## Effectiveness

Eyebright Medical continues to strengthen the roles of the shareholders' meeting. This ensures scientific, effective, and transparent processes in major decision-making, daily operations, and compliance supervision.

### During the Reporting Period

Attendance rates for Directors at Board meetings and committee members at specialized committee meetings reached **100%**

**6** Board meetings held with

**47** proposals approved

**3** Supervisory Committee meetings with

**25** proposals approved

**10** Specialized Committee meetings held with

**34** proposals approved

**1** Shareholders' meeting held with

**12** proposals approved

**NO** proposals were vetoed

## Information Disclosure

The Company strictly follows the Rules Governing the Listing of Stocks on the STAR Market of the Shanghai Stock Exchange and other relevant laws and regulations. It strengthens the management of information disclosure to ensure the authenticity, accuracy, completeness, timeliness and compliance of information disclosure. The Company continuously improves the quality and transparency of information disclosure, and effectively protects the rights and interests of all shareholders, especially minority shareholders.



### Disclosure Performance During the Reporting Period

**4** Regular Reports

**52** Interim Announcements

3 Consecutive Years of **A**-Level Disclosure Rating  
Shanghai Stock Exchange

## Investor Relations Management

### Investor Communication

The Company values the concerns of market participants. To strengthen investor relations management, the Company has formulated the Investor Relations Management System to improve communication efficiency and professionalism. It also added an "Investor Relations" column on the official website and WeChat official account for easy access to information.



### During the Reporting Period



- ✔ Earnings Conferences: 6 periodic report performance briefings were held through multiple online platforms
- ✔ SSE E-Interaction Platform: 80 investor questions were answered with a 100% response rate
- ✔ Investor Open Days: Hosted the "Shareholders Are Coming – Investors Visit Eyebright Medical" event, with over 80 investors attending
- ✔ International Exposure: Became the only medical device listed company of the 25th China International Fair for Investment and Trade
- ✔ 20+ research institutes of financial institutions released nearly 70 research reports and performance comments reviews, and 30+ reports gave rating such as "Buy" and "Overweight" respectively

## Investor Protection

The Company holds the shareholders' general meeting in compliance with the laws and regulations, safeguards the shareholders' rights. It actively listens to investor suggestions on corporate governance and sustainable development.

Through initiatives such as the "2025 World Investor Week", the Company helps investors better understand market rules, risks, and opportunities, fostering a culture of value investing and long-term holding.



## Investor Returns

Eyebright Medical attaches great importance to investor returns and has actively carried out cash dividends since its listing. During the Reporting Period, the Company implemented a distribution plan of RMB 3.50 per 10 shares (tax included).

Total cash dividends amounted to RMB **67.64** million, a **31.33%** increase Y-O-Y

Completed a stock repurchase plan using self-owned or raised funds

Brought back **142,800** shares for a total of RMB **20.04** million

## Market Capitalization Management

Eyebright Medical places great emphasis on market value management. Strictly following the Guidelines for Listed Company Supervision No. 10-Market Value Management, the Company legally employs diversified tools to ensure its investment value rationally reflects its quality.



# Risk Management and Control

The Company has established a risk control system, continuously improved internal policies. By systematically enhancing the ethical competence of all personnel, it strives to achieve long-term, stable, healthy, and sustainable development.

## Compliance and Internal Control Management

The Company prioritizes the construction of an internal control and compliance management system tailored to its business scope and scale. It has established and strictly implemented a dynamic update mechanism, and timely revises and improves the systems according to the changes in laws, regulations, and regulatory policies.

The Company attaches importance to the implementation of compliance management. A transparent platform disseminates compliance policies to all employees (including subsidiaries) to ensure consistent execution.



## Related Party Transactions and Control

To ensure fairness and prevent harm to the Company or minority shareholders, the Company revised the Articles of Association and its Related Party Transaction Decision-Making System during the Reporting Period. It further standardized reporting, abstention, decision-making authority, and disclosure requirements. Related parties abstained from voting on relevant proposals. During the Reporting Period, periodic reviews were conducted, and no related-party transactions requiring submission to the Board of Directors or shareholders' meeting occurred.

### During the Reporting Period

**NO** insider trading occurred

**NO** incidents infringed upon shareholder rights or caused asset loss

**NO** situations harmed the interests of the Company or non-related shareholders

## Management of Public Opinion

In the medical device industry, any quality or safety incidents related to the manufacturing, distribution, or sale of medical devices are prone to attract widespread media attention. It has formulated the Reputation Management System to address reputational risks. This system enhances the ability to identify, assess, monitor, and respond to reputational risks, minimizing negative impacts and protecting brand value.

During the Reporting Period

**NO** major public opinion incidents occurred




## Anti-Fraud and Anti-Corruption Measures

Eyebright Medical upholds "Integrity and Practicality" as one of its core values, strictly following the laws, and adheres to business ethics. The Company continuously improves the business ethics and anti-corruption management system with institutional constraints.

During the Reporting Period

**NO** related issues were reported  
**NO** significant corruption incidents occurred



## Anti-Unfair Competition Practices

Eyebright Medical promotes a fair market environment by strictly adhering to the Anti-Unfair Competition Law of PRC. It has established a full-cycle anti-unfair competition management system to ensure the elimination of unfair competition acts in business activities.

Fair competition criteria are integrated into employee conduct codes. All employees are required to maintain integrity when interacting with competitors, customers, and suppliers.

### During the Reporting Period

Conducted trainings on the Code of Business for new employees with a **100%** training coverage rate  
**NO** unfair competition lawsuits occurred

## Reporting Mechanism

The Company has established a robust complaint and reporting mechanism, encouraging employees, suppliers, and stakeholders to report unethical behavior via phone, email, or mail.

The Company strictly protects the confidentiality of whistleblowers' identities and reported information. It enforces stringent whistleblower protection protocols to safeguard identities and reported content through multilayered confidentiality safeguards.

### Reporting Channels

- Telephone: (86)10-60745730
- Email: [contact@ebmedical.com](mailto:contact@ebmedical.com)



## Information Security & Data Privacy Protection

The Company prioritizes information security and privacy protection by enforcing comprehensive network and computer management policies and building a comprehensive and efficient information system. This system safeguards data security and confidentiality, and ensures stable operations.



### Information Security and Digital Capability

#### Building

##### Training

Conducted AI skills training to empower all staff and improve compliance in information processing

##### System Upgrade

Added security features such as sensitive information interception to ensure the safety of the system

##### Team support

The IT team provides specialized support to any security issues

### Information Security Management

Strictly following the Cybersecurity Law and Data Security Law of PRC, the Company has built a systematic threat prevention and control loop.

#### Main Measures

- Multi-level intelligent firewall system
- Anti-virus software coverage
- Network malware monitoring and blocking
- Regular vulnerability management
- Rapid deployment and verification of high-risk patches
- Business-level whitelist firewall
- Full-link network security monitoring platform

### Customer Privacy Protection

To ensure security throughout the process, the Company has implemented rigorous controls:

- Embedded confidentiality clauses in cooperation agreements or signed separate NDAs
- Clearly defined data protection responsibilities
- Restricted both parties to abide by the confidentiality agreement

#### Case

The CRM system and Cloud System strictly safeguard the privacy data of customers and other partners. Adhering to the principle of data minimization, the Company limits the scope of collecting partners' and personal information.

# Appendix

## Index of Guildlines

### Appendices GRI Standard

GRI Standard Disclosure ID	GRI Standard Disclosure Topic	Report Section
<b>General Disclosure</b>		
<b>GRI2: General Disclosures</b>		
GRI 2-1	Organization Detail	About the Report
GRI 2-2	Entities Included in the Organization’s Sustainability Report	About the Report
GRI 2-3	Reporting Period, Frequency and Contact Point	About the Report
GRI 2-4	Restatements of Information	/
GRI 2-5	External Assurance	Statement of the Board Dircetors
<b>GRI2: Activities and Workers</b>		
GRI 2-6	Activities, Value Chain and other business Relationships	About Us
GRI 2-7	Employee	Employee Development
GRI 2-8	Non-employee workers	/
<b>GRI2: Governance</b>		
GRI 2-9	Governance Structure and Composition	Corporate Governance
GRI 2-10	Nomination and Selection of the Highest Governance Body	Corporate Governance
GRI 2-11	Chair of the Highest Governance Body	Corporate Governance
GRI 2-12	Role of the Highest Governance Body in Overseeing the Management of Impacts	Corporate Governance
GRI 2-13	Delegation of Responsibility for Managing Impacts	Corporate Governance
GRI 2-14	Role of the Highest Governance Body in Sustainability Report	Statement of the Board Dircetors
GRI 2-15	Conflict of Interests	Stakeholder Communication
GRI 2-16	Communication of critical concerns	Stakeholder Communication
GRI 2-17	Collective knowledge of the highest governance body	Corporate Governance
GRI 2-18	Evaluation of the performance of the highest governance body	Corporate Governance
GRI 2-19	Remuneration Policies	Corporate Governance
GRI 2-20	Process to determine remuneration	/
GRI 2-21	Annual Total Compensation Ratio	/

## Appendices GRI Standard

GRI Standard Disclosure ID	GRI Standard Disclosure Topic	Report Section
<b>General Disclosure</b>		
<b>GRI2: Strategy, Policies and Practices</b>		
GRI 2-22	Statement on Sustainable Development Strategy	ESG Strategic Planning
GRI 2-23	Policy Commitment	Pollution Prevention, Employee Development, Corporate Governance
GRI 2-24	Embedding Policy Commitments	Employee Development
GRI 2-25	Processes to Remediate Negative Impacts	Risk Management
GRI 2-26	Mechanisms for Seeking Advice and Raising Concerns	Stakeholder Communication
GRI 2-27	Compliance with Laws and Regulations	Risk Management
GRI 2-28	Membership Associations	Collaborative Industry Advancement
<b>GRI2: Stakeholder Engagement</b>		
GRI 2-29	Approach to Stakeholder Engagement	Stakeholder Communication
GRI 2-30	Collective Bargaining Agreements	Employee Development
<b>GRI3: Material Topics</b>		
GRI 3-1	Process to Determine Material Topics	Materiality Assessment
GRI 3-2	List on Material Topics	Materiality Assessment
GRI 3-3	Management on Material Topics	Materiality Assessment
<b>Economic</b>		
<b>GRI201: Economic Performance</b>		
GRI 201-1	Direct Economic Value Generated and Distributed	Corporate Governance
GRI 201-2	Financial Implications and Other Risks and Opportunities due	Employee Development
GRI 201-3	Defined Benefit Plan Obligations and Other Retirement Plans	Climate Action
<b>GRI203: Indirect Economic Impacts</b>		
Topic management disclosures		Serve The Society
GRI 203-1	Infrastructure Investments and Services Supported	Serve The Society
GRI 203-2	Significant Indirect Economic Impacts	Serve The Society
<b>GRI205: Anti-Corruption</b>		
Topic management disclosures		Risk Management
GRI 205-1	Operations Assessed for Risks Related to Corruption	/
GRI 205-2	Communication and Training About Anti-Corruption Policies	Risk Management
<b>GRI2016: Anti-Unfair Competition</b>		
Topic management disclosures		Risk Management
GRI 206-1	Legal Actions for Anti-unfair Competition, Anti-trust, and Anti-monopoly Practices	Risk Management

## Appendices GRI Standard

GRI Standard Disclosure ID	GRI Standard Disclosure Topic	Report Section
<b>Environment</b>		
<b>GRI301: Material</b>		
Topic management disclosures		Resources Management
GRI 301-2	Recycled Input Materials Used	Resources Management
GRI 301-3	Reclaimed Products and Their Packaging Materials	Resources Management
<b>GRI302: Energy</b>		
Topic management disclosures		Resources Management
GRI 302-1	Energy Consumption within the Organization	Climate Action
GRI 302-3	Energy Intensity	Climate Action
GRI 302-4	Reduction of Energy Consumption	Climate Action
GRI 302-5	Reductions in Energy Requirements of Products and Services	Resources Management
<b>GRI303: Water and Effluents</b>		
GRI 303-1	Interactions with Water as a Shared Resource	Resources Management
GRI 303-2	Management of Water Discharge Related impacts	Resources Management
GRI 303-3	Water Withdrawal	Resources Management
GRI 303-4	Water Discharge	Pollution Prevention
GRI 303-5	Water Consumption	Resources Management
<b>GRI305: Emissions</b>		
Topic management disclosures		Climate Action
GRI 305-1	Direct (Scope 1) GHG Emissions	Climate Action
GRI 305-2	Energy Indirect (Scope 2) GHG Emissions	Climate Action
GRI 305-4	Other Indirect (Scope 3) GHG Emissions	Climate Action
GRI 305-7	Nitrogen Oxides (NOx), Sulfur Oxides (SOx), and Other	/
<b>GRI306: Waste</b>		
GRI 306-1	Waste Generation and Significant Waste-Related Impacts	Pollution Prevention
GRI 306-2	Management of Significant Waste Related Impacts	Pollution Prevention
GRI 306-3	Waste Generated	Pollution Prevention
GRI 306-4	Waste Diverted from Disposal	/
GRI 306-5	Waste Directed to Disposal	/
<b>GRI308: Supplier Environmental Assessment</b>		
Topic management disclosures		Product Responsibility
GRI 308-1	New Suppliers that were Screened Using Environmental	/
GRI 308-2	Negative Environmental Impacts in the Supply Chain and Actions Taken	/

## Appendices GRI Standard

GRI Standard Disclosure ID	GRI Standard Disclosure Topic	Report Section
<b>Social</b>		
<b>GRI401: Employment</b>		
Topic management disclosures		Employee Development
GRI 401-1	New Employee Hires and Employee Turnover	Employee Development
GRI 401-2	Benefits Provided to Full-Time Employees that are not Provided	Employee Development
<b>GRI402: Labor/Management Relations</b>		
Topic management disclosures		Employee Development
<b>GRI403: Occupational Health and Safety</b>		
Topic management disclosures		Employee Development
GRI 403-1	Occupational Health and Safety Management System	Employee Development
GRI 403-2	Hazard Identification, Risk Assessment, and Incident Survey	Employee Development
GRI 403-3	Occupational Health Services	Employee Development
GRI 403-4	Worker Training on Occupational Health and Safety	Employee Development
GRI 403-5	Training of Worker Health	Employee Development
GRI 403-6	Promomtion of Worker Health	Employee Development
GRI 403-7	Prevention and Mitigation of Occupational Health and Safety	Employee Development
GRI 403-8	Health and Safety Management System	Employee Development
GRI 403-9	Work-related Injuries	Employee Development
GRI 403-10	Work-related Ill Health	Employee Development
<b>GRI404: Training and Education</b>		
Topic management disclosures		Employee Development
GRI 404-1	Average Hours of Training per Year per Employee	Employee Development
GRI 404-2	Programs for Upgrading Employee Skills and Transition Assistance Programs	Employee Development
GRI 404-3	Percentage of Employees Receiving Regular Performance and Career Development Reviews	Employee Development
<b>GRI405: Diversity and Equal Opportunity</b>		
Topic management disclosures		Employee Development
GRI 405-1	Diversity of Governance Bodies and Employees	Employee Development, Corporate governance
GRI 405-2	Ratio of Basic Salary and Remuneration of Women to Men	Employee Development
<b>GRI406: Non-Discrimination</b>		
Topic management disclosures		Employee Development
GRI 406-1	Incidents of Discrimination and Corrective Actions Taken	Employee Development

## Appendices GRI Standard

GRI Standard Disclosure ID	GRI Standard Disclosure Topic	Report Section
<b>Social</b>		
<b>GRI407 : Freedom of Association and Collective Bargaining</b>		
Topic management disclosures		Employee Development
GRI 407-1	Operations and Suppliers in which the right to freedom of Association and Collective Bargaining may be at Risk	/
<b>GRI408: Child Labor</b>		
Topic management disclosures		Employee Development
GRI 408-1	Operations and Suppliers at Significant risk for Incidents of Child Labor	/
<b>GRI409: Forced or Compulsory Labor</b>		
Topic management disclosures		Employee Development
GRI 409-1	Operations and Suppliers at Significant risk for Incidents of Forced or Compulsory Labor	/
<b>GRI413: Local Community</b>		
Topic management disclosures		Serve The Society
GRI 413-1	Operations with Local Community Engagement, Impact Assessments, and Development Programs	Serve The Society
GRI 413-2	Operations with Significant Actual and Potential Negative Impacts on Local Communities	/
<b>GRI414: Supplier Social Assessment</b>		
Topic management disclosures		Product Responsibility
GRI 414-1	New Suppliers that were Screened using Social Criteria	Product Responsibility
GRI 414-2	Negative Social Impacts in the Supply Chain and Actions Taken	/
<b>GRI416: Customer Health and Safety</b>		
Topic management disclosures		Product Responsibility
GRI 416-1	Assessment of the Health and Safety Impacts of Product and Service Categories	Product Responsibility
GRI 416-2	Incidents of Non-Compliance Concerning the Health and Safety Impacts of Products and Services	/
<b>GRI417: Marketing and Labeling</b>		
Topic management disclosures		Product Responsibility
GRI 417-1	Requirements for Product and Service Information and Labeling	Product Responsibility
GRI 417-2	Incidents of Non-Compliance Concerning Product and Service	/
GRI 417-3	Information and Labeling	/
<b>GRI418: Customer Privacy</b>		
Topic management disclosures		Product Responsibility
GRI 418-1	Substantiated Complaints Concerning Breaches of Customer Privacy and Losses of Customer Data	/

## Guidelines No. 14 of Shanghai Stock Exchange for Self-Regulation of Listed Companies- Sustainable Development Reports (Trial)

Dimension	Topic	Corresponding Chapter
Environmental	Climate Change Action	Climate Action
	Pollutant Emissions	Pollution Prevention
	Waste Treatment	Waste Treatment
	Ecosystem and Biodiversity Protection	Ecosystem and Biodiversity Protection
	Environmental Compliance Management	Environmental Management
	Energy Utilization	Energy Management
	Water Resource Utilization	Resource Management
	Circular Economy	Resource Management
Social	Rural Revitalization	Rural Revitalization
	Social Contribution	Serve the Society
	Innovation-Driven Development	Innovation-Driven Development
	Science and Technology Ethics	Experimental Ethics
	Supply Chain Safety	Sustainable Supply Chain
	Fair Treatment of SMEs	Customer Service
	Product and Service Safety and Quality	Quality Management
	Data Security and Privacy Protection	Information Security & Data Privacy
Governance	Employees	Employee Development
	Due Diligence	Sustainability Management
	Stakeholder Communication	Stakeholder Communication
	Anti-Fraud and Anti-Corruption	Anti-Fraud and Anti-Corruption Measures
	Measures Anti-Unfair Competition	Anti-Unfair Competition



Eyebright Medical Technology (Beijing) Co., Ltd.  
Stock Code:688050

---

Contact Number:(86)10-6074 5730  
Official Website:[www.ebmedical.com](http://www.ebmedical.com)  
Address: No.9 Xingchang Road, Changping Science Park,  
Changping District, Beijing, China